Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evotec, Chinook Therapeutics Ink Development Pact For Chronic Kidney Diseases Therapies

Author: Vandana Singh | March 01, 2021 06:22am

Chinook Therapeutics Inc (NASDAQ: KDNY) and Evotec SE (OTC:EVTCY) have collaborated for the discovery and development of precision medicine therapies for patients with chronic kidney diseases (CKD).

  • Based on Evotec's proprietary comprehensive molecular datasets, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover and develop precision medicines.
  • The collaboration will utilize Evotec's PanOmics platform, which combines throughput proteomics, high throughput transcriptomics, and cell imaging with PanHunter, its data analysis platform.
  • Chinook will contribute drug discovery and development programs to the collaboration targeting rare kidney diseases such as IgA nephropathy and glomerular diseases.
  • Under the terms of the agreement, Chinook and Evotec will share drug discovery and pre-clinical development responsibilities.
  • Chinook will be responsible for the clinical development and commercialization of product candidates.
  • Evotec will receive an undisclosed upfront payment, research funding, milestone payments, and tiered sales-based royalties.
  • Price Action: KDNY shares closed 1.7% higher at $16.54, and EVTCY closed 0.8% lower at 77.45 on Friday.

Posted In: EVOTF EVTCY KDNY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist